Stock Events

Stock Events

Viridian Therapeutics 

$22.92
29
-$0.04-0.17% Friday 20:00
-$0.12-0.52%Friday 23:30After hours

Statistics

Day High
23.01
Day Low
22.73
52W High
34.29
52W Low
13.18
Volume
48,937
Avg. Volume
-
Mkt Cap
2.6B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.08
-0.83
-0.59
-0.34
Expected EPS
-0.988734
Actual EPS
N/A

Financials

-483.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
70.85MRevenue
-342.6MNet Income

Analyst Ratings

32.75Average Price Target
The highest estimate is 43.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRDN. It's not an investment recommendation.
Amazon
10
AMZN
NVIDIA
10
NVDA
Apple
9
AAPL
AMD
9
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on treatments for eye diseases, allergic and inflammatory diseases, which overlaps with Viridian's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the discovery, development, and commercialization of therapeutics in areas such as viral diseases, inflammatory and fibrotic diseases, which can compete with Viridian's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on creating new possibilities in medicine to cure diseases and improve people's lives, including treatments for cystic fibrosis, competing in the biotech space with Viridian.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, including treatments for inflammatory diseases, which competes with Viridian's focus areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, competing with Viridian in the biopharmaceutical sector.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie's business is focused on delivering transformative therapies in areas such as immunology and oncology, which can compete with Viridian's therapeutic development programs.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, but also has a growing presence in biopharmaceuticals that could compete with Viridian.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a broad portfolio in various therapeutic areas, including respiratory, cardiovascular, and oncology, potentially competing with Viridian's focus on innovative therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global biopharmaceutical company that develops and manufactures healthcare products including medicines and vaccines for a wide range of conditions, competing with Viridian in the healthcare sector.
Merck
MRK
Mkt Cap366B
Merck operates globally and offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing with Viridian in the pharmaceutical and healthcare market.

About

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Show more...
CEO
Stephen F. Mahoney
Employees
252
Country
United States
ISIN
US92790C1045
WKN
000A2QMUH

Listings

STU
DE
1S1.STU
LSE
GB
0K1R.LSE
F
DE
1S1.F
STU
DE
1S1N.STU

0 Comments

Share your thoughts

FAQ

What is Viridian Therapeutics stock price today?▼
The current price of VRDN is $22.92 USD — it has decreased by -0.17% in the past 24 hours. Watch Viridian Therapeutics stock price performance more closely on the chart.
What is Viridian Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Viridian Therapeutics stocks are traded under the ticker VRDN.
Is Viridian Therapeutics stock price growing?▼
VRDN stock has fallen by -0.69% compared to the previous week, the month change is a +8.78% rise, over the last year Viridian Therapeutics has showed a +22.44% increase.
What is Viridian Therapeutics market cap?▼
Today Viridian Therapeutics has the market capitalization of 2.6B
When is the next Viridian Therapeutics earnings date?▼
Viridian Therapeutics is going to release the next earnings report on November 16, 2026.
What were Viridian Therapeutics earnings last quarter?▼
VRDN earnings for the last quarter are -1.05 USD per share, whereas the estimation was -1.03 USD resulting in a -1.48% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viridian Therapeutics revenue for the last year?▼
Viridian Therapeutics revenue for the last year amounts to 70.85M USD.
What is Viridian Therapeutics net income for the last year?▼
VRDN net income for the last year is -342.6M USD.
How many employees does Viridian Therapeutics have?▼
As of September 05, 2026, the company has 252 employees.
In which sector is Viridian Therapeutics located?▼
Viridian Therapeutics operates in the Health & Wellness sector.
When did Viridian Therapeutics complete a stock split?▼
The last stock split for Viridian Therapeutics was on November 13, 2020 with a ratio of 1:15.
Where is Viridian Therapeutics headquartered?▼
Viridian Therapeutics is headquartered in WALTHAM, United States.